Literature DB >> 31682650

STATEMENT FOR TRAVELLERS AND YELLOW FEVER: An Advisory Committee Statement (ACS) Committee to Advise on Tropical Medicine and Travel (CATMAT).

This Statement Was Prepared By P Charlebois.   

Abstract

Year:  2013        PMID： 31682650      PMCID： PMC6802432          DOI： 10.14745/ccdr.v39i00a02

Source DB:  PubMed          Journal:  Can Commun Dis Rep        ISSN： 1188-4169


× No keyword cloud information.
  63 in total

1.  Adverse events following yellow fever vaccination.

Authors: 
Journal:  Wkly Epidemiol Rec       Date:  2001-07-20

2.  Fatal yellow fever in a traveler returning from Amazonas, Brazil, 2002.

Authors: 
Journal:  JAMA       Date:  2002-05-15       Impact factor: 56.272

3.  History of thymoma and yellow fever vaccination.

Authors:  Rachel Barwick Eidex
Journal:  Lancet       Date:  2004 Sep 11-17       Impact factor: 79.321

4.  Early exposure to yellow fever vaccine during pregnancy.

Authors:  Denise P Cavalcanti; Maria Antonieta Salomão; Jorge Lopez-Camelo; Mônica A Pessoto
Journal:  Trop Med Int Health       Date:  2007-07       Impact factor: 2.622

5.  Meeting of Global Advisory Committee on Vaccine Safety, 18-19 June 2008.

Authors: 
Journal:  Wkly Epidemiol Rec       Date:  2008-08-08

6.  Yellow fever vaccination during pregnancy and spontaneous abortion: a case-control study.

Authors:  S de A Nishioka; F R Nunes-Araújo; W P Pires; F A Silva; H L Costa
Journal:  Trop Med Int Health       Date:  1998-01       Impact factor: 2.622

7.  Yellow fever vaccine: recommendations of the Advisory Committee on Immunization Practices (ACIP).

Authors:  J Erin Staples; Mark Gershman; Marc Fischer
Journal:  MMWR Recomm Rep       Date:  2010-07-30

8.  Immunogenicity and tolerability of yellow fever vaccination in 23 French HIV-infected patients.

Authors:  Thierry Pistone; Claire-Hélène Verdière; Marie-Catherine Receveur; Khaled Ezzedine; Marie-Edith Lafon; Denis Malvy
Journal:  Curr HIV Res       Date:  2010-09       Impact factor: 1.581

9.  Advanced age a risk factor for illness temporally associated with yellow fever vaccination.

Authors:  M Martin; L H Weld; T F Tsai; G T Mootrey; R T Chen; M Niu; M S Cetron
Journal:  Emerg Infect Dis       Date:  2001 Nov-Dec       Impact factor: 6.883

10.  Immunogenicity and safety of yellow fever vaccination for 102 HIV-infected patients.

Authors:  Olivia Veit; Matthias Niedrig; Caroline Chapuis-Taillard; Matthias Cavassini; Erik Mossdorf; Patrick Schmid; Hi-Gung Bae; Nadine Litzba; Thomas Staub; Christoph Hatz; Hansjakob Furrer
Journal:  Clin Infect Dis       Date:  2009-03-01       Impact factor: 9.079
View more
  4 in total

1.  Interim Canadian recommendations for the use of a fractional dose of yellow fever vaccine during a vaccine shortage.

Authors: 
Journal:  Can Commun Dis Rep       Date:  2016-08-04

2.  Update regarding interim Canadian recommendations for the use of a fractional dose of yellow fever vaccine during a vaccine shortage.

Authors: 
Journal:  Can Commun Dis Rep       Date:  2016-09-01

Review 3.  Travel vaccines: Update for Canadian pharmacists.

Authors:  Christina Bascom
Journal:  Can Pharm J (Ott)       Date:  2019-10-11

4.  Probiotics and rifaximin for the prevention of travelers' diarrhea: A systematic review and network meta-analysis.

Authors:  Hao Fan; Lei Gao; Zidan Yin; Sheng Ye; Hua Zhao; Qi Peng
Journal:  Medicine (Baltimore)       Date:  2022-10-07       Impact factor: 1.817
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.